Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07091825

Evaluating the Efficacy and Safety of Contact Lens Lubricant in Rigid Gas Permeable Corneal Contact Lens Wearers

This trial aims to evaluate the safety and effectiveness of LACRIFRESH OCU-DRY 0.3% OSD, a contact lens lubricant produced by AVIZOR, S.A. This clinical trial adopts a Multi-center, randomized, open-label, positive parallel-controlled design in accordance with the principles outlined in the Norms on the Quality Management for the Clinical Trials of Medical Devices issued by the National Medical Products Administration of China.

Meanwhile, following statistical requirements, 152 rigid contact lens wearers are planned to be enrolled after screening and meeting the inclusion criteria. Participants will be randomly assigned to groups and provided with lenses, lubricants, and care solutions accordingly. Clinical follow-up assessments are scheduled at 1 week, 1 month, and 3 months after use.

The primary efficacy indexes are the percentage of patients with binocular comfort score ≥ Level 3 at the 1-month follow-up and the percentage of patients with best corrected distance visual acuity with contact lenses for both eyes ≥5.0 at the 1-month follow-up after using the contact lens lubricant. Secondary efficacy indexes include, best corrected distance visual acuity with lenses, visual acuity with lenses, residual diopter, tear break-up time, uncorrected visual acuity, examination of contact lens fitting status, lens assessment, and contact lens lubricant evaluation during the corresponding follow-up periods. Safety indexes include slit lamp examination, fundus examination, IOP, corneal endothelial cell, adverse events, serious adverse events, device defects that may lead to serious adverse events, other device defects during the corresponding follow-up periods.

Recruiting

Interested in participating?

Request Info

Key information

Age range

8 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Aier Intech Eye Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 8 and older, no gender limitation;
  • Rigid gas permeable corneal contact lens (OK lens) wearers;
  • The best corrected distance visual acuity of framed lenses in both eyes can reach 5.0 (5-Point Scale);
  • Be able and willing to comply with all treatments and follow-ups;
  • Be able to understand the purpose of the trial, participate voluntarily and have ICF signed by the subject himself/herself or his/her legal guardian.

Exclusion criteria

  • Patients with only one eye meeting the inclusion criteria.
  • Patients with abnormal clinical abnormalities or systemic diseases affecting the eyes that occurred or is occurring before screening and, in the investigator's judgment, preclude the use of corneal contact lenses.
  • Patients with some eye diseases that affect contact lens wearing: such as acute or chronic eye diseases, conjunctivitis catarrhalis aestiva, glaucoma, corneal abnormalities, keratoconus, etc.
  • Patients with allergies to the components of contact lens or contact lens care solution involved in this trial;
  • Patients who are using or need to use drugs that may cause dry eyes or affect vision and corneal curvature (e.g. immunosuppressant, glucocorticoids, IOP-lowering drugs, low concentration atropine) during the study;
  • Patients with a history of intraocular operation;
  • Patients with abnormal IOP (the single eye IOP <10 mmHg or >21mmHg, or the IOP difference of both eyes >5mmHg), obvious fundus abnormalities, examination of corneal endothelial cell (abnormal ≥ Level 4), or slit-lamp examination abnormalities.
  • Patients with dry eye syndrome or with break up time (BUT) <5s.
  • Subjects who participated in other drug clinical trials within 90 days before screening, and participated in other medical device clinical trials within 30 days;
  • Patients who wore rigid contact lens (including orthokeratology lens) within the past 30 days;
  • Patients who are pregnant, nursing or planning to conceive at the enrollment;
  • Patients with contraindications for wearing rigid contact lenses or unsuitable for wearing rigid contact lenses as indicated by examination results;
  • Other conditions for which the investigator judged the patient unsuitable for inclusion.

Treatment and study plan

LACRIFRESH OCU-DRY 0.3% OSD

Device

Use LACRIFRESH OCU-DRY 0.3% OSD as the daily contact lens lubricant product.

Rigid contact lens lubricant

Device

Use Rigid contact lens lubricant as the daily contact lens lubricant product.

Primary outcomes

  1. Percentage of subjects with comfort scores ≥ Level 3 for both eyes at the 1-month follow-up after using the contact lens lubricant.

    Time frame: 1 month

  2. Percentage of subjects with the best corrected distance visual acuity in both eyes with lenses ≥5.0 at the 1-month follow-up after using the contact lens lubricant.

    Time frame: 1 month

Secondary outcomes

  1. Changes in subjective symptoms assessed by subjective acceptability Scale of National Medical Products Administration(NMPA)

    Time frame: 1 week, 1 month, and 3 months

    According to the Guidelines for Registration Review of Contact Lens Care Products of NMPA, subjective acceptability of contact lens care products is investigated through the investigation of subjective symptoms during follow-up, specifically including evaluations of comfort, visual and operability assessments. Higher scores indicate a more favorable outcome for the endpoint. For comfort assessment, the 6-point scale is defined as follows: Level 0: Painful; Level 1: Extremely uncomfortable; Level 2: Mildly uncomfortable; Level 3: Comfortable; Level 4: Very comfortable; Level 5: Excellent. For visual and operability assessments, the 6-point scale is defined as follows: Level 0: Unacceptable; Level 1: Very poor; Level 2: Poor; Level 3: Good; Level 4: Very good; Level 5: Outstanding.

  2. Changes in best corrected distance visual acuity with lenses

    Time frame: 1 week, and 3 months

  3. Changes in lens wearing vision and residual diopter

    Time frame: 1 week, 1 month, and 3 months

  4. Changes in tear break up time (TBUT)

    Time frame: 1 week, 1 month, and 3 months

  5. Changes in uncorrected visual acuity

    Time frame: 1 week, 1 month, and 3 months

  6. Changes in contact lens fitness examination

    Time frame: 1 week, 1 month, and 3 months

  7. Changes in lens assessment

    Time frame: 1 week, 1 month, and 3 months

  8. Changes in contact lens lubricant evaluation

    Time frame: 1 week, 1 month, and 3 months

  9. Changes in slit-lamp examinations

    Time frame: 1 week, 1 month, and 3 months

  10. Changes in fundus examinations

    Time frame: 1 month and 3 months

  11. Comparison between groups for intraocular pressure (IOP) at each follow-up visit, along with changes relative to baseline

    Time frame: 1 week, 1 month, and 3 months

  12. Comparison between groups for examination of corneal endothelial cell at each follow-up visit, along with changes relative to baselineChanges

    Time frame: 3 months

  13. Incidence of adverse events

    Time frame: From the date of randomization until the occurrence of adverse events, assessed for up to 3 months

  14. Incidence of serious adverse event

    Time frame: From the date of randomization until the occurrence of serious adverse event, assessed for up to 3 months

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Avizor SA

Industry

Registry information

Official study title

A Prospective, Multi-center, Open-Label, Randomized Controlled, Non-Inferiority Clinical Study Evaluating the Efficacy and Safety of Contact Lens Lubricant in Rigid Gas Permeable Corneal Contact Lens Wearers

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jul 29, 2025
Registry last updated
Jul 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.